|Free Dividend Report|
|Stock Splits Calendar|
|ACER Stock Split History|
|Preferred Stock Newsletter|
|ACER Options Chain|
|Stock Message Boards|
Acer Therapeutics (ACER) has 1 split in our ACER split history database. The split for ACER took place on September 21, 2017. This was a 96 for 1000 reverse split, meaning for each 1000 shares of ACER owned pre-split, the shareholder now owned 96 shares. For example, a 1000 share position pre-split, became a 96 share position following the split.
When a company such as Acer Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the ACER split history from start to finish, an original position size of 1000 shares would have turned into 96 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Acer Therapeutics shares, starting with a $10,000 purchase of ACER, presented on a split-history-adjusted basis factoring in the complete ACER split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-17.27%|
|About Acer Therapeutics|
|Acer Therapeutics is a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Co.'s pipeline includes three clinical-stage candidates: EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001 (a taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders and Maple Syrup Urine Disease; and osanetant for the treatment of induced Vasomotor Symptoms where Hormone Replacement Therapy is likely contraindicated. According to our ACER split history records, Acer Therapeutics has had 1 split.|
|ACER Split History Table|
|09/21/2017||96 for 1000|
|Healthcare Stock Splits|
|ACER is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: ACER shares outstanding history